glp 1 receptor agonists and dpp 4 inhibitors Glucagon-like peptide-1 Clinical Use of DPP-4 Inhibitors
Description
Do you think GLP-1 agonists could become the future of obesity management
10.1007/s00125-014-3231-y [DOI] [PubMed] [Google Scholar] 47.Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL
DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?"
oxidative stress, calcium, and glutamate toxicity overload may also lead to energy deficiencies, forming a vicious cycle with -synuclein accumulation
Metabolism 2021;118:154728.ArticlePubMed 77
